When orals attack: how to ensure product access

Share this article:
William Renzo
William Renzo
William Renzo
SVP, dir. of client services, Ogilvy Healthworld Payer Marketing

Therapeutic categories long dominated by IV-infused therapies face oral-product competition. Gilenya's launch into the IV-infused/self-injection dominated multiple sclerosis market is an example. In this scenario, manufacturers of the oral newcomers face some complexities:

• Will adherence rates be on par with IV-infused/self-injectable competitors?

• Is specialty or retail pharmacy the most appropriate distribution channel?

• How should the oral product be priced to effectively compete with injected therapies?

• Will co-pays or coinsurance be the mechanism most plans use to share costs with patients?

• What patient support services will be required?

• What office manager, nurse, and physician education specific to reimbursement and patient services will be necessary?

When oral-dominated therapeutic categories face IV-infused competition, manufacturers of the new infused therapies face different issues:

• Where will the IV-infused product most likely be administered—physician's office, standalone infusion center, hospital? How will these dynamics impact targeting and promotion?

• Do targeted MDs possess the capabilities to administer IV-infused products in the office? If not, what level of education is needed to ensure physicians understand the dynamics surrounding the product's use?

• What benefits will the new product possess over the oral agents that should be considered when establishing price?

• How will health plans manage the IV-infused therapy? Which stakeholders and processes are needed for advocacy, and what must be understood to ensure optimal reimbursement?

• What Medicare Carrier and Contractor Advisory Committee processes are important to understand to streamline reimbursement?

Many areas of the commercialization strategy and marketing mix are impacted, including distribution, contracts and pricing, health economics and outcomes research, HCP and consumer promotion, training, and site-of-care marketing. With the evolution of science and healthcare reform, remaining a step ahead of these paradigm shifts may prove the difference between leaders and followers.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets